Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
histone deacetylase inhibitor |
| gptkbp:approvalYear |
2015
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01XX42
|
| gptkbp:brand |
Farydak
|
| gptkbp:CASNumber |
404950-80-7
|
| gptkbp:chemicalFormula |
C21H23N3O2
|
| gptkbp:contraindication |
severe hepatic impairment
|
| gptkbp:developer |
gptkb:Novartis
|
| gptkbp:eliminationHalfLife |
37 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:hasSMILES |
CC(=O)N(CCCCN)c1ccc(cc1)Nc2ncc(C)nc2O
|
| https://www.w3.org/2000/01/rdf-schema#label |
panobinostat
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits histone deacetylases
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
349.43 g/mol
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
nausea diarrhea fatigue neutropenia thrombocytopenia cardiac arrhythmias |
| gptkbp:UNII |
N2Z4HC1DAE
|
| gptkbp:usedFor |
multiple myeloma
|
| gptkbp:bfsParent |
gptkb:Histone_deacetylase
|
| gptkbp:bfsLayer |
7
|